Science Immunology

The PDF file includes:

  • Fig. S1. SARS-CoV-2 infection activates complement transcription in lung epithelial cells.
  • Fig. S2. SARS-CoV-2 infection activates complement transcription in human lung organoids and primary human bronchial epithelial cells.
  • Fig. S3. C3 protein is induced by SARS-CoV-2 infection of respiratory epithelial cells.
  • Fig. S4. Complement components are expressed in lymphoid, myeloid and epithelial cells.
  • Fig. S5. SARS-CoV2 infection activates complement transcription in bronchoalveolar lavage fluid (BALF) cells.
  • Fig. S6. SARS-CoV2 viral load correlates with C3 mRNA expression in lung tissues of patients with COVID-19.
  • Fig. S7. BALF cells from COVID-19 patients have a CD46 activated signature.
  • Fig. S8. SARS-CoV2 infection minimally affects complement pathways in PBMC across different cell types.
  • Fig. S9. STAT1 and RELA bind SARS-CoV2-induced genes.
  • Fig. S10. STAT1 dependence of SARS-CoV2-induced genes.
  • Fig. S11. Data showing activity of cell-permeable complement factor B inhibitor (CFBi).
  • ig. S12. Percentage N-protein+ and syncytial cells in SARs-CoV2 infected iAECs treated with chemical agents.
  • Table S1. Normalized expression of all transcripts in GSE147507 and SRP257667 and GSEA outputs used in Figure 1.
  • Table S2. List of CD46, C3aR and Interferon alpha/beta target genes curated experimentally for CD46 and from literature for the rest.
  • Table S3. . Differentially expressed genes in SARS-CoV-2-infected cells.
  • Table S4. GSEA-based drug prediction.
  • Table S5. Mass spectrometry data for profiling of CFB inhibitor.
  • Table S6. Data sources used in this study.
  • Table S7. Table of raw data.
F

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1. Normalized expression of all transcripts in GSE147507 and SRP257667 and GSEA outputs used in Figure 1.
  • Table S2. List of CD46, C3aR and Interferon alpha/beta target genes curated experimentally for CD46 and from literature for the rest.
  • Table S3. . Differentially expressed genes in SARS-CoV-2-infected cells.
  • Table S4. GSEA-based drug prediction.
  • Table S5. Mass spectrometry data for profiling of CFB inhibitor.
  • Table S6. Data sources used in this study.
  • Table S7. Table of raw data.